Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMC

Perspective on Intra-articular Injection Cell Therapy for Osteoarthritis Treatment

Im GI.

Narrative Review on Osteoarthritis, Cartilage Damage, Chronic Inflammation, published in Tissue Eng Regen Med (2019) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Tissue Eng Regen Med (2019)
Reported sample size
—
Source database
Europe PMC
PMID
31413940
PMCID
PMC6675827
DOI
10.1007/s13770-018-00176-6
Citations
26

Abstract (original English)

Background Osteoarthritis (OA), the most common arthritis, is one of the most frequently encountered orthopaedic conditions. As a small number of large joints such as knee and hip are affected in OA, OA is an ideal target for local therapy. Although corticosteroid and hyaluronic acid have been traditionally used for joints through intra-articular (IA) injection, IA injection also provides a minimally invasive route to apply cell therapy to treat OA. IA cell therapy has drawn attention because it may provide regeneration of articular cartilage in addition to palliative anti-inflammatory effects. Methods Current progress of IA injection therapy and the author's perspective on this issue are described narratively. Results It is too premature to have any conclusion on the eventual efficacy of IA cell therapy concerning regeneration of articular cartilage based on current data. Prospective radiological and histological data from larger numbers of patients are needed to prove cost effectiveness of IA cell therapy. Conclusions Expanding research in this field will produce further evidences to provide guidance on the eventual effectiveness of IA cell therapy in the future.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Cartilage, ArticularAnimalsHumansOsteoarthritisInjections, Intra-ArticularProspective StudiesCell- and Tissue-Based Therapy

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research